BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Argutus Medical's AKI Test Selected for Innovators Place™


10/25/2012 10:03:48 AM

Cardiff, UK – 25th October 2012 –Argutus Medical, world leader in the development and manufacture of specialised organ injury tests, has been chosen as one of ten companies to display their latest product at the Innovators Place™ during the American Society of Nephrology (ASN) Kidney Week 2012.

The scientific exposition, which takes place from the 1st to the 4th of November at the San Diego Convention Center, USA, will bring together more than 13,000 professionals from around the globe to learn the latest scientific and medical advances in the field of kidney function and disease. Innovators Place™ will be located in the Kidney Week exhibit hall (Halls A-B-C) in a dedicated exhibition space that provides the opportunity for scientific networking between medical device industry trendsetters and the nephrology community.

At the Innovators Place™, Argutus Medical, a subsidiary of EKF Diagnostics (AIM listed worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays) will showcase its new point-of-care test, the RenaStat. Renastat has been developed to detect the early onset of severe acute kidney injury (AKI) in critical care settings. Argutus’ team of AKI experts will provide attendees with an insight into the RenaStat test, as well as scientific information on the development and use of biomarkers for AKI detection.

RenaStat combines novel microfluidic and magnetic immuno-chromatographic technologies (MICT) to allow accurate detection of alpha and pi glutathione S-Transferase (GSTs) in less than 15 minutes from 100µl of patient urine. This rapid, early assessment of biomarkers enables clinicians to promptly identify and carry out appropriate patient treatment.

"Being selected to showcase at such a high profile meeting as Kidney Week 2012, is a privilege and testament to the hard work that has gone into developing RenaStat through years of research and development. Argutus representatives will be on hand to discuss with our renal medicine colleagues how the application of RenaStat can improve patient diagnosis and treatment" said Joe Keenan, General Manager at Argutus.

For more information please visit www.argutusmed.com

www.ekfdiagnostics.com

About Argutus Medical: an EKF Diagnostics Company

Argutus Medical is the world leader in developing and manufacturing specialised organ injury tests. The company primarily focuses on developing ELISA Tests and Rapid Tests for detection of acute injury to the kidney and liver.

Since 2010, Argutus Medical has been part of EKF Diagnostics, whose expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to the manufacture of liquid reagents, the design and building of world-class diagnostic devices and the distribution of rapid test kits for infectious diseases and pregnancy. The EKF range of analysers are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, haemoglobin, haematocrit and HbA1c.

To date, EKF Diagnostics has distributors in more than 70 locations around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES